Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P11488
UPID:
GNAT1_HUMAN
Alternative names:
Transducin alpha-1 chain
Alternative UPACC:
P11488; Q4VBN2
Background:
The Guanine nucleotide-binding protein G(t) subunit alpha-1, also known as Transducin alpha-1 chain, plays a pivotal role in visual signal transduction. It functions as a signal transducer for the rod photoreceptor RHO, essential for normal RHO-mediated light perception by the retina. This protein is involved in the activation and inactivation cycle of GTP and GDP binding, a critical process in the visual signaling pathway.
Therapeutic significance:
Linked to congenital stationary night blindness, the study of Guanine nucleotide-binding protein G(t) subunit alpha-1 offers insights into retinal disorders. Understanding its role could pave the way for innovative treatments for night blindness and related visual impairments.